GlassScriptPhysician profile
Richard Stephen Glick
NPI 1538263884
$4,023.19
in general payments reported to CMS, 2019-2025
27 companies · $669 in 2025
The $669 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $268 · 2021: $926 · 2022: $535 · 2023: $486 · 2024: $876 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960 · Education: $71.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.22 |
| Education | $71.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761.74 | 2019-2025 | |
| Amgen INC. | $725.27 | 2019-2025 | Tavneos, Amjevita |
| Pfizer INC. | $340.15 | 2021-2025 | |
| Janssen Biotech, INC. | $339.87 | 2021-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $325.83 | 2020-2025 | Acthar |
| Ucb, INC. | $262.86 | 2024-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $194.66 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $143.39 | 2022-2024 | Saphnelo |
| Lilly USA, LLC | $116.63 | 2021-2023 | Taltz |
| Alvogen INC | $107.24 | 2023-2025 | Teriparatide |
| Boston Scientific Corporation | $88.23 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.41 | 2020-2025 | Ofev |
| Glaxosmithkline, LLC. | $76.79 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.23 | 2020-2021 | |
| Organon LLC | $54.88 | 2023 | Hadlima |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $50.36 | 2022-2023 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $45.56 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $43.00 | 2024 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $28.34 | 2023 | |
| Horizon Therapeutics Plc | $26.81 | 2021 | |
| Fresenius Kabi USA, LLC | $26.48 | 2023 | |
| Scilex Pharmaceuticals INC. | $22.70 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $21.54 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.80 | 2021 | |
| Medexus Pharma, INC. | $16.86 | 2019 | |
| Spinal Simplicity, LLC | $16.66 | 2024 | Ha Minuteman G3-R |
| Avion Pharmaceuticals | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.